Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?

Zoe Apalla; Eftychios Psarakis; Aimilios Lallas; Alexia Koukouthaki; Athanassios Fassas; Maria Smaragdi

doi:10.5826/dpc.0904a11

Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?

Authors

Zoe Apalla First Dermatology Department, Aristotle University of Thessaloniki, Greece
Eftychios Psarakis State Dermatology and Venereology Department, Hippokration Hospital, Thessaloniki, Greece
Aimilios Lallas First Dermatology Department, Aristotle University of Thessaloniki, Greece
Alexia Koukouthaki State Dermatology and Venereology Department, “Hippokratio” Hospital, Thessaloniki, Greece
Athanassios Fassas Oncology Department, St. Luke’s Private Hospital, Thessaloniki, Greece
Maria Smaragdi State Dermatology and Venereology Department, “Hippokratio” Hospital, Thessaloniki, Greece

Keywords:

psoriasis, adenocarcinoma, apremilast, phosphodiesterase inhibitor, treatment

References

Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387-1399.

Pullamsetti SS, Banat GA, Schmall A, et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene. 2013;32(9):1121-1134.

Downloads

Published

2019-10-31

Issue

2019 Vol 9, No 4 | October

Section

Letter

License

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

Apalla Z, Psarakis E, Lallas A, Koukouthaki A, Fassas A, Smaragdi M. Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?. Dermatol Pract Concept. 2019;9(4):300-301. doi:10.5826/dpc.0904a11